L-Nutra to establish manufacturing center in Abu Dhabi to produce medical and longevity nutrition for the MENA region.
Nutri-technology company L-Nutra has added $36.5 million to its Series D funding round with a strategic investment from Mubadala Investment Company to advance its science-backed nutrition programs designed to promote healthy living and longevity.
The new funding brings the total raised in the round to $83.5 million, and appears to set the stage for significant international expansion as the organizations also revealed plans to form a “joint venture” in Abu Dhabi focused on producing medical nutrition therapies and longevity-focused nutrition for the Middle East and North Africa.
Abu Dhabi–based sovereign investor Mubadala manages a global portfolio of around $330 billion across diverse sectors and has a keen interest in longevity, having backed the likes of Juvena Therapeutics, Juvenescence and Rejuveron in recent times.
“This investment reinforces Abu Dhabi’s ambition to expand as a regional hub for longevity science, preventive health, and advanced nutrition technologies, and operates as a natural extension of the sector capabilities we are building across the UAE’s emerging life sciences ecosystem,” said Mubadala’s Ismail Ali Abdulla.
Founded in 2009 by renowned longevity researcher Valter Longo, L-Nutra has built its business around translating decades of research on fasting and metabolic health into structured nutrition programs. The company is best known as the developer of the “fasting mimicking diet”, a formulation strategy that supplies specific nutrients in precise ratios so that cells respond as if the body is fasting, even while receiving nourishment. The concept underpins both its consumer-facing longevity offerings and its medical nutrition therapies intended for people with chronic conditions. The best-known of these programs is its consumer longevity brand ProLon, which targets metabolic health and healthy aging.
L-Nutra’s work has been supported by dozens of clinical trials and a substantial patent portfolio. The company recently published research conducted with Cedars-Sinai Medical Center and UT Health San Antonio, which found that a five-day ProLon fasting mimicking diet improved markers such as weight and blood sugar while increasing activity in autophagy.
“We are on the cusp of enhancing human healthspan, adding years to our life and life to our years,” said L-Nutra CEO Dr Joseph Antoun. “By reformulating food into clinically validated nutrition programs, we now can support patients and individuals seeking to embark on a healthy longevity journey.”
